[Diabetes and oral contraceptives].

Nordisk medicin · 1971 · vol. 86(40) , pp. 1168 · PMID:5131957 · W2182907172
article OA: closed CC0
View on OpenAlex View on PubMed
AI-generated summary by gemini-2.5-flash-lite, 2026-08-08

Oral contraceptives, containing estrogen and gestagen components, are used by millions of women and may pose risks for those with certain medical conditions, requiring monitoring of urine, blood pressure, and weight.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

20-30 million women use oral contraceptives. The estrogen component, either ethinyl estradiol or mestranol, inhibits the release of the ovum and affects the cervical secretions, the endometrium, the ovaries, and the Fallopian tubes. The gestagen component is derived from 19-nortestosterone or 17-hydroxyprogesterone, and the metabolism of the gestagen component is not fully known. Disposition to thrombosis, liver illness, diabetes, hypertension, amenorrhea, oligo menorrhea, or tumorous changes in the uterus or breasts should not use oral contraceptives. Menstrual disturbances and endometriosis can be controlled by the use of oral contraceptives. Urine samples, blood pressure, and weight should be monitored during oral contraceptive use.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Contraceptives, Oral Contraceptives, Oral Contraceptives, Oral Contraceptives, Oral Estrogens Estrogens Female Humans Menstruation Disturbances Menstruation Disturbances

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-05-14T05:59:13.922585+00:00
License: CC0 · commercial use OK